Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany's ClinIT receives government grant

This article was originally published in Scrip

Executive Summary

The German federal ministry for economics and technology has provided a six-figure grant to Freiburg-based ClinIT and the faculty for databases and information systems of the local Albert-Ludwigs University. The move was made within the Central Innovation Scheme for Medium-sized Businesses development programme. ClinIT intends to develop a new tool for the automatic analysis of data quality in clinical studies and thus optimise the existing scheme when such analysis is carried out for each project. The tool should provide project and data managers who have no specific programming skills with an opportunity to measure and control the quality of data and processes over large-volume libraries and databases, along with cost-effectiveness. ClinIT, which was founded in 2001, specialises in the development and supply of information systems for clinical trials.

You may also be interested in...



Poland's new law fixes prices and trade mark-ups of reimbursed drugs

Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.

Global pharma boosts business in Russia - Why Russia (introduction)

In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.

Russia's president Medvedev wants talks on trials mutual recognition with US and EU

Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC007407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel